BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24252244)

  • 41. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies.
    Iseki E; Marui W; Yamamoto R; Togo T; Katsuse O; Kato M; Iwatsubo T; Kosaka K; Arai H
    Neurosci Lett; 2005 May 20-27; 380(1-2):161-5. PubMed ID: 15854770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice.
    Kishimoto Y; Zhu W; Hosoda W; Sen JM; Mattson MP
    Neuromolecular Med; 2019 Sep; 21(3):239-249. PubMed ID: 31079293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.
    Yu Z; Xu X; Xiang Z; Zhou J; Zhang Z; Hu C; He C
    PLoS One; 2010 Apr; 5(4):e9956. PubMed ID: 20386702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
    Ryan BJ; Bengoa-Vergniory N; Williamson M; Kirkiz E; Roberts R; Corda G; Sloan M; Saqlain S; Cherubini M; Poppinga J; Bogtofte H; Cioroch M; Hester S; Wade-Martins R
    J Neurosci; 2021 Apr; 41(16):3731-3746. PubMed ID: 33563726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease.
    Brys I; Nunes J; Fuentes R
    Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death.
    Wang YT; Lin HC; Zhao WZ; Huang HJ; Lo YL; Wang HT; Lin AM
    Sci Rep; 2017 Apr; 7():45741. PubMed ID: 28401906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.
    Kelly R; Bemelmans AP; Joséphine C; Brouillet E; McKernan DP; Dowd E
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
    Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
    Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
    Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
    Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
    Vernon AC; Johansson SM; Modo MM
    BMC Neurosci; 2010 Jan; 11():1. PubMed ID: 20051106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
    Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
    Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.